Your browser doesn't support javascript.
loading
SARS-CoV-2 vaccination in patients with lymphoid hematologic malignancies / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 249-252, 2023.
Artículo en Chino | WPRIM | ID: wpr-988978
ABSTRACT
Patients with lymphoid hematologic malignancies have a poor prognosis after developing SARS-CoV-2 infection, and their seropositivity rate after SARS-CoV-2 vaccination is lower than that of the healthy population. Since most clinical trials of SARS-CoV-2 vaccines do not include immunodeficient populations, the safety and efficacy of various types of SARS-CoV-2 vaccines for patients with lymphoid hematologic malignancies are unclear. Therefore, physicians should decide whether patients with lymphoid hematologic malignancies receive SARS-CoV-2 vaccination and the timing, type and dose of vaccine after taking into full consideration the patient's immune status, type of treatment and the risk of SARS-CoV-2 infection.

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2023 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2023 Tipo del documento: Artículo